Munich Reinsurance Co Stock Corp in Munich Buys Shares of 15,124 IQVIA Holdings Inc. $IQV

Munich Reinsurance Co Stock Corp in Munich acquired a new position in shares of IQVIA Holdings Inc. (NYSE:IQV – Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 15,124 shares of the medical research company’s stock, valued at approximately $3,444,000.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Claret Asset Management Corp grew its holdings in shares of IQVIA by 1.1% during the third quarter. Claret Asset Management Corp now owns 4,527 shares of the medical research company’s stock worth $860,000 after purchasing an additional 49 shares in the last quarter. Versant Capital Management Inc grew its holdings in shares of IQVIA by 6.3% during the third quarter. Versant Capital Management Inc now owns 899 shares of the medical research company’s stock worth $171,000 after purchasing an additional 53 shares in the last quarter. Leonard Rickey Investment Advisors P.L.L.C. grew its holdings in shares of IQVIA by 3.3% during the fourth quarter. Leonard Rickey Investment Advisors P.L.L.C. now owns 1,814 shares of the medical research company’s stock worth $409,000 after purchasing an additional 58 shares in the last quarter. Brookstone Capital Management grew its holdings in shares of IQVIA by 2.2% during the fourth quarter. Brookstone Capital Management now owns 2,931 shares of the medical research company’s stock worth $661,000 after purchasing an additional 63 shares in the last quarter. Finally, Private Advisor Group LLC grew its holdings in shares of IQVIA by 1.0% during the third quarter. Private Advisor Group LLC now owns 6,122 shares of the medical research company’s stock worth $1,163,000 after purchasing an additional 63 shares in the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently commented on IQV. Wall Street Zen raised IQVIA from a “hold” rating to a “buy” rating in a report on Sunday, April 19th. Truist Financial cut their price objective on IQVIA from $290.00 to $245.00 and set a “buy” rating for the company in a report on Thursday, February 19th. Mizuho set a $215.00 price objective on IQVIA in a report on Monday, February 23rd. Stifel Nicolaus cut their target price on IQVIA from $273.00 to $220.00 and set a “buy” rating for the company in a research note on Friday, February 6th. Finally, Royal Bank Of Canada started coverage on IQVIA in a research note on Tuesday, March 3rd. They issued an “outperform” rating and a $221.00 target price for the company. Two analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, the company has an average rating of “Buy” and an average target price of $226.63.

View Our Latest Research Report on IQVIA

IQVIA Price Performance

Shares of IQV stock opened at $162.48 on Friday. The stock has a market cap of $27.57 billion, a price-to-earnings ratio of 20.67, a PEG ratio of 1.60 and a beta of 1.39. The business’s fifty day moving average is $170.03 and its 200 day moving average is $202.73. IQVIA Holdings Inc. has a twelve month low of $134.65 and a twelve month high of $247.04. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.09.

IQVIA (NYSE:IQV – Get Free Report) last issued its quarterly earnings results on Thursday, February 5th. The medical research company reported $3.42 earnings per share for the quarter, topping the consensus estimate of $3.40 by $0.02. The company had revenue of $4.36 billion for the quarter, compared to analysts’ expectations of $4.24 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.34%.The firm’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same period in the prior year, the firm earned $3.12 earnings per share. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. Research analysts expect that IQVIA Holdings Inc. will post 11.5 EPS for the current fiscal year.

IQVIA Company Profile

(Free Report)

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.

Further Reading

• Five stocks we like better than IQVIA

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV – Free Report).